

Editorial

Primary Biliary Cirrhosis

Shahverdi E^{1,2*} and Rekabdar Y³¹Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Iran²Student Research Committee, Baqiyatallah University of Medical Sciences, Iran³School of Medicine, Tehran Medical Sciences Branch, Islamic Azad University, Iran***Corresponding author:** Ehsan Shahverdi, Iranian Blood Transfusion Organization bldg. Hemmat exp. way Tehran- Iran**Received:** February 03, 2017; **Accepted:** February 10, 2017; **Published:** February 13, 2017

Editorial

Primary biliary cirrhosis (PBC) is an autoimmune liver disease of adults that can progress to liver fibrosis and cirrhosis. PBC mainly affects middle-aged women [1,2]. The mean proportion of female is 92% and the prevalence is increasing over the time [3]. The etiology of PBC is not clearly known thus it is believed that the disease appears in genetic predisposed population in exposure of environmental factors such as infection, chemicals and smoking [4].

The diagnosis is made based on combination of clinical signs and symptoms, abnormal liver function tests presenting for more than six months and detectable AMA (Anti Mitochondrial Antibody) in serum [4]. Ninety to ninety-five percent of patients are AMA positive although AMA is found in less than 1% of normal population [5].

About 60% of patients are asymptomatic at the time of diagnosis. Serum liver function tests and liver histology are used to assess severity of the disease and severities in symptomatic patients are less than symptomatic patients. The most common symptom in symptomatic patients is pruritus, 25% of patients have non-specific symptoms such right upper quadrant pain and lethargy, 20% of cases have jaundice, variceal hemorrhage or ascites. In asymptomatic patients the main reason of death is non-hepatic malignancies thus most important cause of death in symptomatic patient is liver failure or variceal bleeding [6].

Three groups of medications are effective in PBC treatment: Immuno-modulators, anti-fibrotics and anti-cholestatics. Currently, the first-line therapy is ursodeoxycholic acid (UDCA), an anti cholestatic [7]. In end stages especially when serum bilirubin level reaches to 100 μ mol/ l (5.9mg/dl) the best option is liver transplant [8].

References

1. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. *New England Journal of Medicine*. 2005; 353: 1261-1273.
2. Hohenester S, Oude-Elferink RP, Beuers U. Primary biliary cirrhosis. *Seminars in immunopathology*; 2009: 31; 283-307.
3. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. *Journal of hepatology*. 2012; 56: 1181-1188.
4. Kumagi T, Heathcote E. Primary biliary cirrhosis. *Orphanet journal of rare diseases*. 2008; 3: 1.
5. Gershwin ME, Mackay I, Sturgess A, Coppel R. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. *The Journal of Immunology*. 1987; 138: 3525-3531.
6. Prince M, Chetwynd A, Craig W, Metcalf J, James O. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. *Gut*. 2004; 53: 865-870.
7. Poupon R. Trials in primary biliary cirrhosis: need for the right drugs at the right time. *Hepatology*. 2004; 39: 900-902.
8. Christensen E, Gunson B, Neuberger J. Optimal timing of liver transplantation for patients with primary biliary cirrhosis: use of prognostic modelling. *Journal of hepatology*. 1999; 30: 285-292.